Can oral terbinafine be given to a woman who is four months pregnant?

Oral Terbinafine in Pregnancy at 4 Months

Oral terbinafine should generally be avoided during pregnancy, including at 4 months gestation, unless the fungal infection is life-threatening and no safer alternatives exist.

FDA Classification and Official Guidance

Terbinafine is classified as FDA Pregnancy Category B, meaning animal studies have shown no harm to the fetus, but adequate human studies are lacking 1. The FDA drug label explicitly states: "Because treatment of onychomycosis can be postponed until after pregnancy is completed, it is recommended that terbinafine not be initiated during pregnancy" 1.

Clinical Context and Risk Assessment

At 4 months (approximately 16 weeks), the patient is in the second trimester, past the critical period of organogenesis (first 13 weeks). This timing is relevant because:

• Teratogenic risk is highest during the first trimester when major organ systems are forming
• The second trimester carries lower theoretical risk for structural malformations
• However, fetal exposure still occurs and long-term effects remain uncertain

Evidence from Recent Studies

The most robust recent evidence comes from a 2020 Danish nationwide registry study of 1,650,649 pregnancies 2. This large-scale cohort study found:

• No increased risk of major malformations with oral terbinafine exposure (prevalence odds ratio 1.01,95% CI 0.63-1.62)
• No increased risk of spontaneous abortion (hazard ratio 1.06,95% CI 0.86-1.32)
• Absolute risk differences were minimal (0.04% for malformations, 0.13% for abortion)

A 2022 systematic review corroborated these findings, concluding that terbinafine exposure during pregnancy showed "absence of an increased risk of congenital malformations, spontaneous abortion, preterm birth, small for gestational age, low birth weight, or stillbirth" 3.

Guideline Recommendations

The 2007 IDSA Sporotrichosis Guidelines provide the most relevant clinical guidance 4:

• Terbinafine is FDA Category B and "not expected to harm an unborn baby"
• However, pregnant patients should discuss risks and benefits with their physicians
• For non-life-threatening cutaneous fungal infections, "it may be prudent to wait until pregnancy is completed"
• Life-threatening infections should be treated with amphotericin B, which can be safely administered during pregnancy

Clinical Decision Algorithm

For non-life-threatening fungal infections (onychomycosis, tinea):

1. Defer treatment until after delivery - this is the safest approach
2. If treatment cannot be deferred, use topical antifungals as first-line (clotrimazole, miconazole, nystatin) 5
3. For localized cutaneous infections, consider local hyperthermia as an alternative 4

For severe or life-threatening fungal infections:

1. Use amphotericin B as the drug of choice 4
2. Oral terbinafine may be considered only after careful risk-benefit discussion if amphotericin B is not feasible

Important Caveats

• Terbinafine passes into breast milk at a 7:1 milk-to-plasma ratio, so breastfeeding considerations also apply 1
• The clinical significance of recent reassuring data 2, 3 has not yet been incorporated into official FDA labeling or major guidelines
• Most fungal skin and nail infections are not urgent and can safely wait until after pregnancy
• Azole antifungals should be avoided in pregnancy due to established teratogenic potential 4

Practical Recommendation

Do not initiate oral terbinafine at 4 months of pregnancy for routine fungal infections. The condition (likely onychomycosis or dermatophytosis) is not life-threatening and treatment can be safely postponed until after delivery. If the patient has already been taking terbinafine and discovers she is pregnant, reassure her that recent large-scale studies show no increased risk, but discontinue the medication and defer further treatment until postpartum. Use topical antifungals if symptomatic relief is needed during pregnancy.